Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease

Neurobiology of Disease

Volumn 23, Issue 3, 2006, Pages 502-511

  Fukuchi, Ken ichiro ^a   Tahara, Kazuki ^a   Kim, Hong Duck ^a   Maxwell, J Adam ^a   Lewis, Terry L ^b   Accavitti Loper, Mary Ann ^b   Kim, Helen ^c   Ponnazhagan, Selvarangan ^d   Lalonde, Robert ^e  

^a UNIVERSITY OF ILLINOIS   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITÉ DE ROUEN   (France)

Author keywords

Amyloid plaque; Amyloid protein; Gene therapy; Immune therapy; Transgenic mouse; Vaccine

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN ANTIBODY; IMMUNOGLOBULIN; PHOSPHATE BUFFERED SALINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; AMYLOID BETA PROTEIN; ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT;

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; HIPPOCAMPUS; HUMAN; HUMAN CELL; INFLAMMATION; INJECTION SITE; MOUSE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; BRAIN; C57BL MOUSE; CELL STRAIN COS1; CELL SURVIVAL; CERCOPITHECUS; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; SENILE PLAQUE; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; BRAIN; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COS CELLS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; SENILE PLAQUES; TREATMENT OUTCOME;

EID: 33747178096     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.04.012     Document Type: Article

References (58)

1. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., and Hyman B.T. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7 (2001) 369-372
2. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., and Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22 (2002) 7873-7878
3. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000) 916-919
4. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., and Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2023-2028
5. Bayer T.A., Wirths O., Majtenyi K., Hartmann T., Multhaup G., Beyreuther K., and Czech C. Key factors in Alzheimer's disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol. 11 (2001) 1-11
6. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., and Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64 (2005) 94-101
7. Brockmann E.C., Cooper M., Stromsten N., Vehniainen M., and Saviranta P. Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions. J. Immunol. Methods 296 (2005) 159-170
8. Burger C., Gorbatyuk O.S., Velardo M.J., Peden C.S., Williams P., Zolotukhin S., Reier P.J., Mandel R.J., and Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10 (2004) 302-317
9. Burger C., Nash K., and Mandel R.J. Recombinant adeno-associated viral vectors in the nervous system. Hum. Gene Ther. 16 (2005) 781-791
10. Calhoun M.E., Burgermeister P., Phinney A.L., Stalder M., Tolnay M., Wiederhold K.H., Abramowski D., Sturchler-Pierrat C., Sommer B., Staufenbiel M., and Jucker M. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 14088-14093
11. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
12. Davidson B.L., Stein C.S., Heth J.A., Martins I., Kotin R.M., Derksen T.A., Zabner J., Ghodsi A., and Chiorini J.A. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3428-3432
13. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci.U. S. A. 98 (2001) 8850-8855
14. Di Pasquale G., Davidson B.L., Stein C.S., Martins I., Scudiero D., Monks A., and Chiorini J.A. Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9 (2003) 1306-1312
15. Ehrengruber M.U., Hennou S., Bueler H., Naim H.Y., Deglon N., and Lundstrom K. Gene transfer into neurons from hippocampal slices: comparison of recombinant Semliki Forest Virus, adenovirus, adeno-associated virus, lentivirus, and measles virus. Mol. Cell. Neurosci. 17 (2001) 855-871
16. Ferrer I., Boada R.M., Sanchez Guerra M.L., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14 (2004) 11-20
17. Fukuchi K.i., Accavitti-Loper M.A., Kim H.D., Tahara K., Cao Y., Lewis T.L., Caughey R.C., Kim H., and Lalonde R. Amelioration of amyloid load by anti-A[beta] single-chain antibody in Alzheimer mouse model. Biochem. Biophys. Res. Commun. 344 (2006) 79-86
18. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
19. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., and Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3228-3233
20. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
21. Kay M.A., Manno C.S., Ragni M.V., Larson P.J., Couto L.B., McClelland A., Glader B., Chew A.J., Tai S.J., Herzog R.W., Arruda V., Johnson F., Scallan C., Skarsgard E., Flake A.W., and High K.A. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24 (2000) 257-261
22. Kim H.D., Kong F.K., Cao Y., Lewis T.L., Kim H., Tang D.C., and Fukuchi K. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain. Neurosci. Lett. 370 (2004) 218-223
23. Klein R.L., Hamby M.E., Sonntag C.F., Millard W.J., King M.A., and Meyer E.M. Measurements of vector-derived neurotrophic factor and green fluorescent protein levels in the brain. Methods 28 (2002) 286-292
24. Klein R.L., Dayton R.D., Leidenheimer N.J., Jansen K., Golde T.E., and Zweig R.M. Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of Tau or green fluorescent proteins. Mol. Ther. 13 (2006) 517-527
25. Klugmann M., Wymond S.C., Leichtlein C.B., Klaussner B.K., Dunning J., Fong D., Young D., and During M.J. AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. Mol. Cell. Neurosci. 28 (2005) 347-360
26. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6448-6453
27. Lambert M.P., Viola K.L., Chromy B.A., Chang L., Morgan T.E., Yu J., Venton D.L., Krafft G.A., Finch C.E., and Klein W.L. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79 (2001) 595-605
28. Li L., Cao D., Garber D.W., Kim H., and Fukuchi K. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am. J. Pathol. 163 (2003) 2155-2164
29. Liu R., Yuan B., Emadi S., Zameer A., Schulz P., McAllister C., Lyubchenko Y., Goud G., and Sierks M.R. Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry 43 (2004) 6959-6967
30. Lo Y.M., Wong I.H., Zhang J., Tein M.S., Ng M.H., and Hjelm N.M. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 59 (1999) 3899-3903
31. Manno C.S., Chew A.J., Hutchison S., Larson P.J., Herzog R.W., Arruda V.R., Tai S.J., Ragni M.V., Thompson A., Ozelo M., Couto L.B., Leonard D.G., Johnson F.A., McClelland A., Scallan C., Skarsgard E., Flake A.W., Kay M.A., High K.A., and Glader B. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (2003) 2963-2972
32. Manoutcharian K., Acero G., Munguia M.E., Becerril B., Massieu L., Govezensky T., Ortiz E., Marks J.D., Cao C., Ugen K., and Gevorkian G. Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. Neurobiol. Dis. 17 (2004) 114-121
33. McCown T.J. Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther. 5 (2005) 333-338
34. McCown T.J., Xiao X., Li J., Breese G.R., and Samulski R.J. Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713 (1996) 99-107
35. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
36. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConlogue L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
37. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 (2003) 448-452
38. Nitsch R.M. Immunotherapy of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 18 (2004) 185-189
39. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
40. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
41. Paganetti P., Calanca V., Galli C., Stefani M., and Molinari M. beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J. Cell Biol. 168 (2005) 863-868
42. Paterna J.C., Moccetti T., Mura A., Feldon J., and Bueler H. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther. 7 (2000) 1304-1311
43. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., and Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 (2002) 1379
44. Prosch S., Stein J., Staak K., Liebenthal C., Volk H.D., and Kruger D.H. Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol. Chem. Hoppe-Seyler 377 (1996) 195-201
45. Racke M.M., Boone L.I., Hepburn D.L., Parsadainian M., Bryan M.T., Ness D.K., Piroozi K.S., Jordan W.H., Brown D.D., Hoffman W.P., Holtzman D.M., Bales K.R., Gitter B.D., May P.C., Paul S.M., and DeMattos R.B. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25 (2005) 629-636
46. Richichi C., Lin E.J., Stefanin D., Colella D., Ravizza T., Grignaschi G., Veglianese P., Sperk G., During M.J., and Vezzani A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 24 (2004) 3051-3059
47. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
48. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., and Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2 (1996) 864-870
49. Sigurdsson E.M., Wisniewski T., and Frangione B. A safer vaccine for Alzheimer's disease?. Neurobiol. Aging 23 (2002) 1001-1008
50. Solomon B., and Frenkel D. Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology. J. Neural. Transm. (2002) 321-325
51. Verma I.M., and Weitzman M.D. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 74 (2005) 711-738
52. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
53. Weksler M.E. The immunotherapy of Alzheimer's disease. Immun. Ageing 1 (2004) 2
54. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., and Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23 (2003) 3745-3751
55. Worn A., and Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305 (2001) 989-1010
56. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16 (1996) 921-932
57. Yankner B.A., Duffy L.K., and Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 (1990) 279-282
58. Zolotukhin S., Potter M., Zolotukhin I., Sakai Y., Loiler S., Fraites Jr. T.J., Chiodo V.A., Phillipsberg T., Muzyczka N., Hauswirth W.W., Flotte T.R., Byrne B.J., and Snyder R.O. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002) 158-167